Oral contraceptive use and BRCA penetrance: A case-only study

Cancer Epidemiology Biomarkers and Prevention

Volumn 18, Issue 7, 2009, Pages 2107-2113

  Pasanisi, Patrizia ^a   Hédelin, Guy ^b   Berrino, Jacopo ^a   Chang Claude, Jenny ^c   Hermann, Silke ^c   Steel, Michael ^d   Haites, Neva ^e   Hart, Jacob ^f   Peled, Ronit ^g   Gafà, Lorenzo ^h   Leggio, Laura ^h   Traina, Adele ⁱ   Amodio, Rosalba ⁱ   Primic Zakelj, Maja ^j   Zadnik, Vesna ^j   Veidebaum, Toomas ^k   Tekkel, Mare ^l   Berrino, Franco ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY OF ST ANDREWS   (United Kingdom)

^e UNIVERSITY OF ABERDEEN   (United Kingdom)

^f TEL AVIV UNIVERSITY   (Israel)

^g BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^h Ragusa Section   (Italy)

ⁱ Ospedale Civico M Ascoli   (Italy)

^j INSTITUTE OF ONCOLOGY   (Slovenia)

^k Department of Oncology and Immunology ^*  (Estonia)

^l NATIONAL INSTITUTE FOR HEALTH DEVELOPMENT   (Estonia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

ADULT; AGE DISTRIBUTION; ARTICLE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; ESTONIA; FAMILY HISTORY; FEMALE; FRANCE; GENE DELETION; GENE MUTATION; GENETIC TRAIT; GERMANY; HETEROZYGOTE; HUMAN; ISRAEL; ITALY; MAJOR CLINICAL STUDY; ONCOGENE; ORAL CONTRACEPTION; OVARY CANCER; PENETRANCE; PRIORITY JOURNAL; PROBABILITY; SLOVENIA; UNITED KINGDOM;

ADOLESCENT; ADULT; AGE OF ONSET; BRCA2 PROTEIN; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CONTRACEPTIVES, ORAL; EUROPE; FEMALE; GENES, BRCA1; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LOGISTIC MODELS; MODELS, GENETIC; PEDIGREE; PENETRANCE; QUESTIONNAIRES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; YOUNG ADULT;

EID: 67650418137     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-09-0024     Document Type: Article

References (57)

1. Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst 1999;91:1310-6.
2. Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 2002;94:1365-72.
3. Easton DF, Bishop DT, Ford D, Crockford GP. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1993;52:678-701.
4. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998;62:676-89.
5. Narod S, Ford D, Devilee P, et al. Breast Cancer Linkage Consortium. Genetic heterogeneity of breast-ovarian cancer revisited. Am J Hum Genet 1995;57:957-8.
6. Anglian Breast Cancer Study Group. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br J Cancer 2000;83:1301-8.
7. Bonadona V, Sinilnikova OM, Chopin S, et al. Contribution of BRCA1 and BRCA2 germ-line mutations to the incidence of breast cancer in young women: results from a prospective population-based study in France. Genes Chromosomes Cancer 2005;43:404-13.
8. Hopper JL, Southey MC, Dite GS, et al. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study. Cancer Epidemiol Biomarkers Prev 1999;8:741-7.
9. Loman N, Bladstrom A, Johannsson O, Borg A, Olsson H. Cancer incidence in relatives of a population-based set of cases of early-onset breast cancer with a known BRCA1 and BRCA2 mutation status. Breast Cancer Res 2003;5:R175-86.
10. Peto J, Collins N, Barfoot R, et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 1999;91:943-9.
11. Risch HA, McLaughlin JR, Cole DE, et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst 2006;98:1694-706.
12. Thorlacius S, Struewing JP, Hartge P, et al. Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet 1998;352:1337-9.
13. Narod SA. Modifiers of risk of hereditary breast cancer. Oncogene 2006;25:5832-6.
14. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72:1117-30.
15. Chang-Claude J, Becher H, Eby N, Bastert G, Wahrendorf J, Hamann U. Modifying effect of reproductive risk factors on the age at onset of breast cancer for German BRCA1 mutation carriers. J Cancer Res Clin Oncol 1997;123:272-9.
16. Narod SA, Goldgar D, Cannon-Albright L, et al. Risk modifiers in carriers of BRCA1 mutations. Int J Cancer 1995;64:394-8.
17. Berrino F, Pasanisi P, Berrino J, Curtosi P, Bellati C. A European caseonly study on familial breast cancer. IARC Sci Publ 2002;156:63-5.
18. Pasanisi P, Berrino J, Fusconi E, Curtosi P, Berrino F. A European Case-Only Study (COS) on familial breast cancer. J Nutr 2005;135:3040-1S.
19. Kotsopoulos J, Narod SA. Towards a dietary prevention of hereditary breast cancer. Cancer Causes Control 2005;16:125-38.
20. Nkondjock A, Ghadirian P. Epidemiology of breast cancer among BRCA mutation carriers: an overview. Cancer Lett 2004;205:1-8.
21. Bermejo-Perez MJ, Marquez-Calderon S, Llanos-Mendez A. Effectiveness of preventive interventions in BRCA1/2gene mutation carriers: a systematic review. Int J Cancer 2007;121:225-31.
22. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Breast cancer. In Combined Estrogen-Progesteron Contraceptives and Combined Estrogen-Progesteron Menopausal Therapy. IARC Monographs n 91. Lyon: IARC Press; 2007. p. 50-5.
23. Henderson BE, Feigelson HS. Hormonal carcinogenesis. Carcinogenesis 2000;21:427-33.
24. Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. Lancet Oncol 2001;2:133-40.
25. Kumle M, Weiderpass E, Braaten T, Persson I, Adami HO, Lund E. Use of oral contraceptives and breast cancer risk: The Norwegian-Swedish Women's Lifestyle and Health Cohort Study. Cancer Epidemiol Biomarkers Prev 2002;11:1375-81.
26. Olsson H, Moller TR, Ranstam J. Early oral contraceptive use and breast cancer among premenopausal women: final report from a study in southern Sweden. J Natl Cancer Inst 1989;81:1000-4.
27. Velentgas P, Daling JR. Risk factors for breast cancer in younger women. J Natl Cancer Inst Monogr 1994;16:15-24.
28. Narod SA, Dube MP, Klijn J, et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2002;94:1773-9.
29. Brohet RM, Goldgar DE, Easton DF, et al. Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, the IBCCS Collaborating Group 813. J Clin Oncol 2007;25:3831-6.
30. Jernstrom H, Loman N, Johannsson OT, Borg A, Olsson H. Impact of teenage oral contraceptive use in a population-based series of early-onset breast cancer cases who have undergone BRCA mutation testing. Eur J Cancer 2005;41:2312-20.
31. Henningson M, Johansson U, Borg A, Olsson H, Jernstrom H. CYP17 genotype is associated with short menstrual cycles, early oral contraceptive use and BRCA mutation status in young healthy women. Mol Hum Reprod 2007;13:231-6.
32. Rothman KJ, Greenland S. Modern Epidemiology. Philadelphia: Lippincott; 1998.
33. Antoniou AC, Easton DF. Models of genetic susceptibility to breast cancer. Oncogene 2006;25:5898-905.
34. Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer 1994;73:643-51.
35. Federico M, Maiorana A, Mangone L, et al. Identification of families with hereditary breast and ovarian cancer for clinical and mammographic surveillance: the Modena Study Group proposal. Breast Cancer Res Treat 1999;55:213-21.
36. Frank TS, Deffenbaugh AM, Reid JE, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 2002;20:1480-90.
37. Shattuck-Eidens D, Oliphant A, McClure M, et al. BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA 1997;278:1242-50.
38. Berry DA, Parmigiani G, Sanchez J, Schildkraut J, Winer E. Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst 1997;89:227-38.
39. Parmigiani G, Berry D, Aguilar O. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 1998;62:145-58.
40. Andersen TI. Genetic heterogeneity in breast cancer susceptibility. Acta Oncol 1996;35:407-10.
41. Parkin D, Whelan SL, Ferlay J. Cancer Incidence in Five Continents. IARC Scientific Publication n.155. Lyon: IARC Press; 2002.
42. Capocaccia R, Verdecchia A, Micheli A, Sant M, Gatta G, Berrino F. Breast cancer incidence and prevalence estimated from survival and mortality. Cancer Causes Control 1990;1:23-9.
43. Verdecchia A, Capocaccia R, Egidi V, Golini A. A method for the estimation of chronic disease morbidity and trends from mortality data. Stat Med 1989;8:201-16.
44. Berrino F, Capocaccia R, Esteve J, et al. Survival of cancer patients in Europe: the EUROCARE-2Study. IARC Scientific Publications N 151. Lyon: IARC Press; 1999.
45. Berrino F, Capocaccia R, Coleman P, et al. Survival of Cancer patients in Europe: the EUROCARE-3 Study. Ann Oncol 2003;14(S5):9-155.
46. De Angelis G, De Angelis R, Frova L, Verdecchia A. MIAMOD: a computer package to estimate chronic disease morbidity using mortality and survival data. Comput Methods Programs Biomed 1994;44:99-107.
47. Radice P. Mutations of BRCA genes in hereditary breast and ovarian cancer. J Exp Clin Cancer Res 2002;21:9-12.
48. Roudgari H, Miedzybrodzka ZH, Haites NE. Probability estimation models for prediction of BRCA1 and BRCA2 mutation carriers: COS compares favorably with other models. Fam Cancer 2007;7:199-212.
49. Tan DS, Marchio C, Reis-Filho JS. Hereditary breast cancer: from molecular pathology to tailored therapies. J Clin Pathol 2008;61:1073-82.
50. Fan S, Wang J, Yuan R, et al. BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science 1999;284:1354-6.
51. Monteiro AN. BRCA1: the enigma of tissue-specific tumor development. Trends Genet 2003;19:312-5.
52. Welcsh PL, King MC. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet 2001;10:705-13.
53. Friedman LC, Kramer RM. Reproductive issues for women with BRCA mutations. J Natl Cancer Inst Monogr 2005;34:83-6.
54. Narod SA, Risch H, Moslehi R, et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 1998;339:424-8.
55. Narod SA, Sun P, Ghadirian P, et al. Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet 2001;357:1467-70.
56. Narod SA, Sun P, Risch HA. Ovarian cancer, oral contraceptives, and BRCA mutations. N Engl J Med 2001;345:1706-7.
57. Modan B, Hartge P, Hirsh-Yechezkel G, et al. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 2001;345:235-40.